CoChat
Sign Up
Cited by 290

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Effect of rapamycin on aging and age-related diseases—past and future

Selvarani, Ramasamy, Mohammed, Sabira, Richardson, Arlan·2021·GeroScience
DOI 10.1007/s11357-020-00274-1PMC PMC8190242
Open this paper in CoChat — free account

Abstract

In 2009, rapamycin was reported to increase the lifespan of mice when implemented later in life. This observation resulted in a sea-change in how researchers viewed aging. This was the first evidence that a pharmacological agent could have an impact on aging when administered later in life, i.e., an intervention that did not have to be implemented early in life before the negative impact of aging. Over the past decade, there has been an explosion in the number of reports studying the effect of rapamycin on various diseases, physiological functions, and biochemical processes in mice. In this review, we focus on those areas in which there is strong evidence for rapamycin’s effect on aging and age-related diseases in mice, e.g., lifespan, cardiac disease/function, central nervous system, immune system, and cell senescence. We conclude that it is time that pre-clinical studies be focused on taking rapamycin to the clinic, e.g., as a potential treatment for Alzheimer’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11357-020-00274-1

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A notable feature of effective anti-aging interventions is the diverse mechanisms by which they target different aging hallmarks in different tissues to maintain healthspan of the whole organism.

    “a notable feature of effective anti-aging interventions, such as lowered insulin/IGF-1 signaling 296 and disruption of the TORC1 complex 296,297 , is the diverse mechanisms by which they target different aging hallmarks in different tissues to maintain healthspan of the whole organism.”

    From Hallmarks of aging: An expanding universe (2023) · cites this paper as [297]

    The Summary (page not available in our copy) reports that rapamycin affects cancer, cardiac and brain aging, and senescence across cell types in mice, supporting broad effects in different tissues. The review does not establish the broader claim that effective anti-aging interventions characteristically use diverse mechanisms to target different aging hallmarks and thereby maintain whole-organism healthspan. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 156

  1. Rapamycin’s secrets unearthed. C&EN Global Enterprise. 2016;94(29):26–30. doi:https://doi.org/10.1021/cen-09429-cover. · DOI
  2. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253(5022):905–9. · DOI
  3. Brown EJ, Albers MW, Bum Shin T, ichikawa K, Keith CT, Lane WS et al. A mammalian protein targeted by G1-arresting rapamycin–receptor complex. Nature. 1994;369(6483):756–758. doi:https://doi.org/10.1038/369756a0. · DOI · Paper page
  4. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78(1):35–43. https://doi.org/10.1016/0092-8674(94)90570-3. · DOI · Paper page
  5. Ehninger D, Neff F, Xie K. Longevity, aging and rapamycin. Cell Mol Life Sci. 2014;71(22):4325–46. https://doi.org/10.1007/s00018-014-1677-1. · DOI
  6. Richardson A, Galvan V, Lin AL, Oddo S. How longevity research can lead to therapies for Alzheimer’s disease: the rapamycin story. Exp Gerontol. 2015;68:51–8. https://doi.org/10.1016/j.exger.2014.12.002. · DOI
  7. Arriola Apelo SI, Lamming DW. Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island. J Gerontol A Biol Sci Med Sci. 2016;71(7):841–9. https://doi.org/10.1093/gerona/glw090. · DOI
  8. Swindell WR. Rapamycin in mice. Aging (Milano). 2017;9(9):1941–2. https://doi.org/10.18632/aging.101289. · DOI
  9. Kaeberlein M, Powers RW 3rd, Steffen KK, Westman EA, Hu D, Dang N, et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science. 2005;310(5751):1193–6. https://doi.org/10.1126/science.1115535. · DOI · Paper page
  10. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004;14(10):885–90. https://doi.org/10.1016/j.cub.2004.03.059. · DOI · Paper page
  11. Powers RW, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 2006;20(2):174–84. · DOI · Paper page
  12. Fok WC, Chen Y, Bokov A, Zhang Y, Salmon AB, Diaz V, et al. Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PLoS One. 2014;9(1):e83988. https://doi.org/10.1371/journal.pone.0083988. · DOI
  13. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011;66(2):191–201. https://doi.org/10.1093/gerona/glq178. · DOI · Paper page
  14. Nadon NL, Strong R, Miller RA, Harrison DE. NIA interventions testing program: investigating putative aging intervention agents in a genetically heterogeneous mouse model. EBioMedicine. 2017;21:3–4. https://doi.org/10.1016/j.ebiom.2016.11.038. · DOI
  15. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014;13(3):468–77. https://doi.org/10.1111/acel.12194. · DOI
  16. Bitto A, Ito TK, Pineda VV, LeTexier NJ, Huang HZ, Sutlief E, et al. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. Elife. 2016;5. https://doi.org/10.7554/eLife.16351. · DOI · Paper page
  17. Khapre RV, Kondratova AA, Patel S, Dubrovsky Y, Wrobel M, Antoch MP, et al. BMAL1-dependent regulation of the mTOR signaling pathway delays aging. Aging (Albany NY). 2014;6(1):48–57. https://doi.org/10.18632/aging.100633. · DOI
  18. Siegmund SE, Yang H, Sharma R, Javors M, Skinner O, Mootha V, et al. Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome. Hum Mol Genet. 2017;26(23):4588–605. https://doi.org/10.1093/hmg/ddx341. · DOI · Paper page
  19. Johnson SC, Yanos M, Sangesland M, Bitto A, Castanza A, Gagnidze A, et al. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet. 2015;6:247. · DOI
  20. Reifsnyder PC, Ryzhov S, Flurkey K, Anunciado-Koza RP, Mills I, Harrison DE, et al. Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J-Lepr(db) mice. Ann N Y Acad Sci. 2018;1418(1):106–17. https://doi.org/10.1111/nyas.13557. · DOI
  21. Zhang X, Li L, Chen S, Yang D, Wang Y, Zhang X, et al. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7(4):412–25. https://doi.org/10.4161/auto.7.4.14541. · DOI · Paper page
  22. Bhattacharya B, Akram M, Balasubramanian I, Tam KK, Koh KX, Yee MQ, et al. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells. Cancer Biol Ther. 2012;13(1):34–42. https://doi.org/10.4161/cbt.13.1.18437. · DOI
  23. Ferrara-Romeo I, Martinez P, Saraswati S, Whittemore K, Graña-Castro O, Thelma Poluha L, et al. The mTOR pathway is necessary for survival of mice with short telomeres. Nat Commun. 2020;11(1):1168. https://doi.org/10.1038/s41467-020-14962-1. · DOI
  24. Fang Y, Hill CM, Darcy J, Reyes-Ordoñez A, Arauz E, McFadden S, et al. Effects of rapamycin on growth hormone receptor knockout mice. Proc Natl Acad Sci U S A. 2018;115(7):E1495–E503. https://doi.org/10.1073/pnas.1717065115. · DOI
  25. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle. 2009;8(23):3831–7. https://doi.org/10.4161/cc.8.23.10070. · DOI
  26. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, et al. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011;10(6):1059–71. https://doi.org/10.1158/1535-7163.mct-10-0792. · DOI
  27. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcΔ716 mice. Proc Natl Acad Sci. 2008;105(36):13544–9. https://doi.org/10.1073/pnas.0800041105. · DOI
  28. Koehl GE, Spitzner M, Ousingsawat J, Schreiber R, Geissler EK, Kunzelmann K. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice. Oncogene. 2010;29(10):1553–60. https://doi.org/10.1038/onc.2009.435. · DOI
  29. Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, et al. eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila). 2014;7(1):169–78. https://doi.org/10.1158/1940-6207.CAPR-13-0299. · DOI
  30. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2–8. https://doi.org/10.1038/ncb2641. · DOI · Paper page
  31. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice. Aging (Milano). 2012;4(10):709–14. https://doi.org/10.18632/aging.100498. · DOI
  32. Christy B, Demaria M, Campisi J, Huang J, Jones D, Dodds SG, et al. p53 and rapamycin are additive. Oncotarget. 2015;6(18):15802–13. https://doi.org/10.18632/oncotarget.4602. · DOI
  33. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis. Aging (Albany NY). 2012;4(10):715–22. https://doi.org/10.18632/aging.100496. · DOI
  34. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol. 2010;176(5):2092–7. https://doi.org/10.2353/ajpath.2010.091050. · DOI
  35. Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN, et al. Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Cancer Biol Ther. 2014;15(5):586–92. https://doi.org/10.4161/cbt.28164. · DOI
  36. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13(6):748–53. https://doi.org/10.1038/nm1560. · DOI
  37. Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, et al. Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors. Aging (Albany NY). 2013;5(2):100–10. https://doi.org/10.18632/aging.100533. · DOI
  38. Hurez V, Dao V, Liu A, Pandeswara S, Gelfond J, Sun L, et al. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell. 2015;14(6):945–56. https://doi.org/10.1111/acel.12380. · DOI
  39. Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag. 2007;3(2):191–201. https://doi.org/10.2147/vhrm.2007.3.2.191. · DOI
  40. Park H-J, Kim H-Y, Lee J-M, Choi YS, Park C-S, Kim D-B, et al. Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion. Circ J. 2012;76(4):868–75. https://doi.org/10.1253/circj.CJ-11-1021. · DOI
  41. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002;43(8):1170–80. · DOI · Paper page
  42. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J. 2007;71(2):220–5. https://doi.org/10.1253/circj.71.220. · DOI
  43. Jabs A, Göbel S, Wenzel P, Kleschyov AL, Hortmann M, Oelze M, et al. Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. 2008;51(22):2130–8. https://doi.org/10.1016/j.jacc.2008.01.058. · DOI
  44. Imanishi T, Kobayashi K, Kuki S, Takahashi C, Akasaka T. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis. 2006;189(2):288–96. https://doi.org/10.1016/j.atherosclerosis.2005.12.031. · DOI
  45. Jahrling JB, Lin A-L, DeRosa N, Hussong SA, Van Skike CE, Girotti M, et al. mTOR drives cerebral blood flow and memory deficits in LDLR(−/−) mice modeling atherosclerosis and vascular cognitive impairment. J Cereb Blood Flow Metab. 2018;38(1):58–74. https://doi.org/10.1177/0271678X17705973. · DOI
  46. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol. 2005;46(4):481–6. https://doi.org/10.1097/01.fjc.0000177985.14305.15. · DOI
  47. Zhao L, Ding T, Cyrus T, Cheng Y, Tian H, Ma M, et al. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. Br J Pharmacol. 2009;156(5):774–85. https://doi.org/10.1111/j.1476-5381.2008.00080.x. · DOI
  48. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia. Atherosclerosis. 2008;198(1):39–48. https://doi.org/10.1016/j.atherosclerosis.2007.09.019. · DOI
  49. Ross C, Salmon A, Strong R, Fernandez E, Javors M, Richardson A, et al. Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Milano). 2015;7(11):964–73. https://doi.org/10.18632/aging.100843. · DOI
  50. Buss SJ, Muenz S, Riffel JH, Malekar P, Hagenmueller M, Weiss CS, et al. Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol. 2009;54(25):2435–46. https://doi.org/10.1016/j.jacc.2009.08.031. · DOI
  51. Di R, Wu X, Chang Z, Zhao X, Feng Q, Lu S, et al. S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt. Biochem J. 2012;441(1):199–207. https://doi.org/10.1042/bj20110033. · DOI
  52. Flynn JM, O’Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell. 2013;12(5):851–62. https://doi.org/10.1111/acel.12109. · DOI
  53. Dai DF, Karunadharma PP, Chiao YA, Basisty N, Crispin D, Hsieh EJ, et al. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell. 2014;13(3):529–39. https://doi.org/10.1111/acel.12203. · DOI
  54. Urfer SR, Kaeberlein TL, Mailheau S, Bergman PJ, Creevy KE, Promislow DEL, et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. Geroscience. 2017;39(2):117–27. https://doi.org/10.1007/s11357-017-9972-z. · DOI · Paper page
  55. Stoica L, Zhu PJ, Huang W, Zhou H, Kozma SC, Costa-Mattioli M. Selective pharmacogenetic inhibition of mammalian target of rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc Natl Acad Sci U S A. 2011;108(9):3791–6. https://doi.org/10.1073/pnas.1014715108. · DOI · Paper page
  56. Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One. 2011;6(9):e25416. https://doi.org/10.1371/journal.pone.0025416. · DOI · Paper page
  57. Siman R, Cocca R, Dong Y. The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy. PLoS One. 2015;10(11):e0142340-e. doi:https://doi.org/10.1371/journal.pone.0142340. · DOI
  58. Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–18. https://doi.org/10.1038/nrneurol.2012.263. · DOI · Paper page
  59. Lin A-L, Jahrling JB, Zhang W, DeRosa N, Bakshi V, Romero P, et al. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease. J Cereb Blood Flow Metab. 2017;37(1):217–26. · DOI
  60. Tramutola A, Lanzillotta C, Barone E, Arena A, Zuliani I, Mosca L et al. Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. Translational neurodegeneration. 2018;7:28-. doi:https://doi.org/10.1186/s40035-018-0133-9. · DOI
  61. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson’s disease. J Neurosci. 2010;30(3):1166–75. https://doi.org/10.1523/jneurosci.3944-09.2010. · DOI
  62. Zhu F, Fan M, Xu Z, Cai Y, Chen Y, Yu S, et al. Neuroprotective effect of rapamycin against Parkinson’s disease in mice. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018;47(5):465–72.
  63. Bai X, Wey MC-Y, Fernandez E, Hart MJ, Gelfond J, Bokov AF, et al. Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. Pathobiol Aging Age Relat Dis. 2015;5(1):28743. https://doi.org/10.3402/pba.v5.28743. · DOI
  64. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15(3):433–42. https://doi.org/10.1093/hmg/ddi458. · DOI · Paper page
  65. King MA, Hands S, Hafiz F, Mizushima N, Tolkovsky AM, Wyttenbach A. Rapamycin inhibits polyglutamine aggregation independently of autophagy by reducing protein synthesis. Mol Pharmacol. 2008;73(4):1052–63. https://doi.org/10.1124/mol.107.043398. · DOI · Paper page
  66. Halloran J, Hussong SA, Burbank R, Podlutskaya N, Fischer KE, Sloane LB, et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience. 2012;223:102–13. https://doi.org/10.1016/j.neuroscience.2012.06.054. · DOI
  67. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, et al. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. Aging Cell. 2012;11(2):326–35. https://doi.org/10.1111/j.1474-9726.2011.00791.x. · DOI
  68. Van Skike CE, Lin A-L, Roberts Burbank R, Halloran JJ, Hernandez SF, Cuvillier J et al. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging. Aging Cell. 2020;19(1):e13057-e. doi:https://doi.org/10.1111/acel.13057. · DOI
  69. Cambiaghi M, Cursi M, Magri L, Castoldi V, Comi G, Minicucci F, et al. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. Neuropharmacology. 2013;67:1–7. https://doi.org/10.1016/j.neuropharm.2012.11.003. · DOI
  70. Cox RL, Calderon de Anda F, Mangoubi T, Yoshii A. Multiple critical periods for rapamycin treatment to correct structural defects in Tsc-1-suppressed brain. Front Mol Neurosci. 2018, 409;11. https://doi.org/10.3389/fnmol.2018.00409. · DOI
  71. Hadamitzky M, Herring A, Keyvani K, Doenlen R, Krügel U, Bösche K, et al. Acute systemic rapamycin induces neurobehavioral alterations in rats. Behav Brain Res. 2014;273:16–22. https://doi.org/10.1016/j.bbr.2014.06.056. · DOI
  72. Hadamitzky M, Herring A, Kirchhof J, Bendix I, Haight MJ, Keyvani K, et al. Repeated systemic treatment with rapamycin affects behavior and amygdala protein expression in rats. Int J Neuropsychopharmacol. 2018;21(6):592–602. https://doi.org/10.1093/ijnp/pyy017. · DOI
  73. Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Milano). 2019;11(19):8048–67. https://doi.org/10.18632/aging.102355. · DOI
  74. Weichhart T, Hengstschläger M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15(10):599–614. https://doi.org/10.1038/nri3901. · DOI
  75. Jones RG, Pearce EJ. MenTORing immunity: mTOR signaling in the development and function of tissue-resident immune cells. Immunity. 2017;46(5):730–42. · DOI
  76. Snyder JP, Amiel E. Regulation of dendritic cell immune function and metabolism by cellular nutrient sensor mammalian target of rapamycin (mTOR). Front Immunol. 2019;9:3145. · DOI
  77. Nouwen LV, Everts B. Pathogens MenTORing macrophages and dendritic cells: manipulation of mTOR and cellular metabolism to promote immune escape. Cells. 2020;9(1):161. · DOI
  78. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. 2008;29(4):565–77. · DOI · Paper page
  79. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med. 2009;15(3):267. · DOI
  80. Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, McClaren JL, et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol. 2013;14(12):1266. · DOI
  81. Goldberg EL, Smithey MJ, Lutes LK, Uhrlaub JL, Nikolich-Žugich J. Immune memory–boosting dose of rapamycin impairs macrophage vesicle acidification and curtails glycolysis in effector CD8 cells, impairing defense against acute infections. J Immunol. 2014;193(2):757–63. · DOI · Paper page
  82. Ferrer IR, Wagener ME, Robertson JM, Turner AP, Araki K, Ahmed R, et al. Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol. 2010;185(4):2004–8. · DOI
  83. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25(3):585–621. · DOI · Paper page
  84. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2004;26(5):867–74. https://doi.org/10.1093/carcin/bgh296. · DOI
  85. Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, et al. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford Progeria syndrome Cells. Sci Transl Med. 2011;3(89):89ra58. https://doi.org/10.1126/scitranslmed.3002346. · DOI · Paper page
  86. Houssaini A, Breau M, Kanny Kebe SA, Marcos E, Lipskaia L, Rideau D et al. mTOR pathway activation drives lung cell senescence and emphysema. JCI insight. 2018;3(3) e93203. · DOI
  87. Chen X, Xu H, Hou J, Wang H, Zheng Y, Li H, et al. Epithelial cell senescence induces pulmonary fibrosis through Nanog-mediated fibroblast activation. Aging (Milano). 2019;12(1):242–59. https://doi.org/10.18632/aging.102613. · DOI
  88. Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell. 2009;5(3):279–89. https://doi.org/10.1016/j.stem.2009.06.017. · DOI · Paper page
  89. Hinojosa CA, Mgbemena V, Van Roekel S, Austad SN, Miller RA, Bose S, et al. Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence. Exp Gerontol. 2012;47(12):958–65. · DOI
  90. Lesniewski LA, Seals DR, Walker AE, Henson GD, Blimline MW, Trott DW, et al. Dietary rapamycin supplementation reverses age-related vascular dysfunction and oxidative stress, while modulating nutrient-sensing, cell cycle, and senescence pathways. Aging Cell. 2017;16(1):17–26. https://doi.org/10.1111/acel.12524. · DOI
  91. Chung CL, Lawrence I, Hoffman M, Elgindi D, Nadhan K, Potnis M, et al. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. Geroscience. 2019;41(6):861–9. https://doi.org/10.1007/s11357-019-00113-y. · DOI · Paper page
  92. Quarles E, Basisty N, Chiao YA, Merrihew G, Gu H, Sweetwyne MT, et al. Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. Aging Cell. 2020;19(2):e13086. https://doi.org/10.1111/acel.13086. · DOI
  93. Sills AM, Artavia JM, DeRosa BD, Ross CN, Salmon AB. Long-term treatment with the mTOR inhibitor rapamycin has minor effect on clinical laboratory markers in middle-aged marmosets. Am J Primatol. 2019;81(2):e22927. https://doi.org/10.1002/ajp.22927. · DOI · Paper page
  94. Kaeberlein M, Galvan V. Rapamycin and Alzheimer’s disease: time for a clinical trial? Sci Transl Med. 2019;11(476):eaar4289. https://doi.org/10.1126/scitranslmed.aar4289. · DOI
  95. Brattström C, Säwe J, Jansson B, Lönnebo A, Nordin J, Zimmerman JJ, et al. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit. 2000;22(5):537–44. · DOI
  96. Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol. 2011;6(2):125–9. https://doi.org/10.1007/s11523-011-0174-9. · DOI
  97. Cohen EEW. mTOR: the mammalian target of replication. J Clin Oncol. 2008;26(3):348–9. https://doi.org/10.1200/jco.2007.14.3164. · DOI
  98. Ceschi A, Heistermann E, Gros S, Reichert C, Kupferschmidt H, Banner NR, et al. Acute sirolimus overdose: a multicenter case series. PLoS One. 2015;10(5):e0128033. https://doi.org/10.1371/journal.pone.0128033. · DOI
  99. Mita M, Mita A. Are we ready to move away from nature? The rapamycin story. Target Oncol. 2011;6(2):63–4. https://doi.org/10.1007/s11523-011-0183-8. · DOI
  100. Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects. Exp Gerontol. 2018;105:53–69. https://doi.org/10.1016/j.exger.2017.12.026. · DOI · Paper page
  101. Pavlakis M, Goldfarb-Rumyantzev AS. Diabetes after transplantation and sirolimus: what’s the connection? : Am Soc Nephrol. 2008;19:1255. · DOI
  102. Dumas SN, Lamming DW. Next generation strategies for geroprotection via mTORC1 inhibition. J Gerontol A Biol Sci Med Sci. 2019;75(1):14–23. https://doi.org/10.1093/gerona/glz056. · DOI
  103. Vemulapalli S, Mita A, Alvarado Y, Sankhala K, Mita M. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Target Oncol. 2011;6(1):29. · DOI
  104. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando). 2014;28(3):126–33. · DOI
  105. Vina J, Lloret A. Why women have more Alzheimer’s disease than men: gender and mitochondrial toxicity of amyloid-β peptide. J Alzheimers Dis. 2010;20(s2):S527–S33. · DOI · Paper page
  106. Lin A-L, Zheng W, Halloran JJ, Burbank RR, Hussong SA, Hart MJ, et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s disease. J Cereb Blood Flow Metab. 2013;33(9):1412–21. https://doi.org/10.1038/jcbfm.2013.82. · DOI
  107. Jiang T, Tan L, Zhu X-C, Zhang Q-Q, Cao L, Tan M-S, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2014;39(13):2949–62. · DOI · Paper page
  108. Moreno-Gonzalez I, Estrada LD, Sanchez-Mejias E, Soto C. Smoking exacerbates amyloid pathology in a mouse model of Alzheimer’s disease. Nat Commun. 2013;4(1):1–10. · DOI
  109. Bielas J, Herbst A, Widjaja K, Hui J, Aiken JM, McKenzie D, et al. Long term rapamycin treatment improves mitochondrial DNA quality in aging mice. Exp Gerontol. 2018;106:125–31. https://doi.org/10.1016/j.exger.2018.02.021. · DOI
  110. Kloskowska E, Pham TM, Nilsson T, Zhu S, Oberg J, Codita A, et al. Cognitive impairment in the Tg6590 transgenic rat model of Alzheimer’s disease. J Cell Mol Med. 2010;14(6B):1816–23. https://doi.org/10.1111/j.1582-4934.2009.00809.x. · DOI
  111. Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J Neurosci. 2013;33(15):6245–56. https://doi.org/10.1523/jneurosci.3672-12.2013. · DOI
  112. Geula C, Nagykery N, Wu C-K. Amyloid-β deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathol. 2002;103(1):48–58. · DOI
  113. Mansfield K. Marmoset models commonly used in biomedical research. Comp Med. 2003;53(4):383–92.
  114. Chen C, Liu Y, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009;2(98):ra75. https://doi.org/10.1126/scisignal.2000559. · DOI · Paper page
  115. Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, et al. Rapamycin extends life and health in C57BL/6 mice. J Gerontol A Biol Sci Med Sci. 2014;69(2):119–30. https://doi.org/10.1093/gerona/glt056. · DOI
  116. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol. 2010;176(6):3062–72. https://doi.org/10.2353/ajpath.2010.090872. · DOI
  117. Stelzer MK, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF. Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila). 2010;3(12):1542–51. https://doi.org/10.1158/1940-6207.CAPR-10-0228. · DOI
  118. Voskamp P, Bodmann CA, Rebel HG, Koehl GE, Tensen CP, Bouwes Bavinck JN, et al. Rapamycin impairs UV induction of mutant-p53 overexpressing cell clusters without affecting tumor onset. Int J Cancer. 2012;131(6):1267–76. https://doi.org/10.1002/ijc.27391. · DOI
  119. Nogueira LM, Dunlap SM, Ford NA, Hursting SD. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer. 2012;19(1):57–68. https://doi.org/10.1530/erc-11-0213. · DOI
  120. Lashinger LM, Malone LM, Brown GW, Daniels EA, Goldberg JA, Otto G, et al. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer. Cancer Prev Res (Phila). 2011;4(7):1041–51. https://doi.org/10.1158/1940-6207.capr-11-0023. · DOI
  121. Hussein O, Tiedemann K, Murshed M, Komarova SV. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett. 2012;314(2):176–84. https://doi.org/10.1016/j.canlet.2011.09.026. · DOI
  122. Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res. 2011;17(9):2863–73. https://doi.org/10.1158/1078-0432.ccr-09-3202. · DOI
  123. Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, Tamura M, et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol. 2011;6(5):852–63. https://doi.org/10.1097/JTO.0b013e31820e1a25. · DOI
  124. Ohara T, Takaoka M, Toyooka S, Tomono Y, Nishikawa T, Shirakawa Y, et al. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells. Cancer Sci. 2011;102(7):1344–9. · DOI
  125. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia. Atherosclerosis. 2008;198(1):39–48. · DOI
  126. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 2003;107(12):1664–70. https://doi.org/10.1161/01.cir.0000057979.36322.88. · DOI
  127. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004;109(24):3050–5. · DOI
  128. Boluyt MO, Li ZB, Loyd AM, Scalia AF, Cirrincione GM, Jackson RR. The mTOR/p70 S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo. Cardiovasc Drugs Ther. 2004;18(4):257–67. · DOI
  129. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res. 2005;68(2):224–34. · DOI
  130. Gao X-M, Wong G, Wang B, Kiriazis H, Moore X-L, Su Y-D, et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens. 2006;24(8):1663–70. · DOI
  131. Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome–associated PTPN11 mutation. J Clin Invest. 2011;121(3):1026–43. · DOI
  132. Chen X, Zeng S, Zou J, Chen Y, Yue Z, Gao Y, et al. Rapamycin attenuated cardiac hypertrophy induced by isoproterenol and maintained energy homeostasis via inhibiting NF-κB activation. Mediat Inflamm. 2014;2014:868753.
  133. Van Skike CE, Jahrling JB, Olson AB, Sayre NL, Hussong SA, Ungvari Z, et al. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol. 2018;314(4):H693–h703. https://doi.org/10.1152/ajpheart.00570.2017. · DOI
  134. Zhang W, He H, Song H, Zhao J, Li T, Wu L, et al. Neuroprotective effects of salidroside in the MPTP mouse model of Parkinson’s disease: involvement of the PI3K/Akt/GSK3β pathway. J Parkinsons Dis. 2016;2016:1. · DOI
  135. Masini D, Bonito-Oliva A, Bertho M, Fisone G. Inhibition of mTORC1 signaling reverts cognitive and affective deficits in a mouse model of Parkinson’s disease. Front Neurol. 2018;9:208. https://doi.org/10.3389/fneur.2018.00208. · DOI
  136. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci. 2009;12(9):1152–8. https://doi.org/10.1038/nn.2369. · DOI
  137. Wang X, Seekaew P, Gao X, Chen J. Traumatic brain injury stimulates neural stem cell proliferation via mammalian target of rapamycin signaling pathway activation. eNeuro. 2016;3(5):ENEURO.0162–16.2016. doi:https://doi.org/10.1523/ENEURO.0162-16.2016. · DOI · Paper page
  138. Shen W, Lu K, Wang J, Wu A, Yue Y. Activation of mTOR signaling leads to orthopedic surgery-induced cognitive decline in mice through β-amyloid accumulation and tau phosphorylation. Mol Med Rep. 2016;14(4):3925–34. · DOI
  139. Liu W, Guo JN, Mu J, Tian L, Zhou D. Rapamycin protects sepsis-induced cognitive impairment in mouse hippocampus by enhancing autophagy. Cell Mol Neurobiol. 2017;37(7):1195–205. https://doi.org/10.1007/s10571-016-0449-x. · DOI
  140. Yuan H, Wu G, Zhai X, Lu B, Meng B, Chen J. Melatonin and rapamycin attenuate isoflurane-induced cognitive impairment through inhibition of neuroinflammation by suppressing the mTOR signaling in the hippocampus of aged mice. Front Aging Neurosci. 2019;11:314. · DOI
  141. Zhou M, Li W, Huang S, Song J, Kim Ju Y, Tian X, et al. mTOR inhibition ameliorates cognitive and affective deficits caused by disc1 knockdown in adult-born dentate granule neurons. Neuron. 2013;77(4):647–54. https://doi.org/10.1016/j.neuron.2012.12.033. · DOI
  142. Lorne E, Zhao X, Zmijewski JW, Liu G, Park Y-J, Tsuruta Y, et al. Participation of mammalian target of rapamycin complex 1 in toll-like receptor 2–and 4–induced neutrophil activation and acute lung injury. Am J Respir Cell Mol Biol. 2009;41(2):237–45. · DOI
  143. Li Z, Chen L, Sun Y, Li G. Rapamycin relieves inflammation of experimental autoimmune encephalomyelitis by altering the balance of Treg/Th17 in a mouse model. Neurosci Lett. 2019;705:39–45. · DOI
  144. Kim EY, Ner-Gaon H, Varon J, Cullen AM, Guo J, Choi J, et al. Post-sepsis immunosuppression depends on NKT cell regulation of mTOR/IFNγ in NK cells. J Clin Invest. 2020;130:3238. · DOI
  145. Fielhaber JA, Carroll SF, Dydensborg AB, Shourian M, Triantafillopoulos A, Harel S, et al. Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis. J Immunol. 2012;188(9):4535–42. · DOI
  146. Goldberg EL, Romero-Aleshire MJ, Renkema KR, Ventevogel MS, Chew WM, Uhrlaub JL, et al. Lifespan-extending caloric restriction or m TOR inhibition impair adaptive immunity of old mice by distinct mechanisms. Aging Cell. 2015;14(1):130–8. · DOI
  147. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle. 2009;8(12):1888–95. · DOI · Paper page
  148. Zhuo L, Cai G, Liu F, Fu B, Liu W, Hong Q, et al. Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging. Mech Ageing Dev. 2009;130(10):700–8. · DOI
  149. Leontieva OV, Demidenko ZN, Gudkov AV, Blagosklonny MV. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. PLoS One. 2011;6(10):e26126. · DOI
  150. Zhang S, Cai G, Fu B, Feng Z, Ding R, Bai X, et al. SIRT1 is required for the effects of rapamycin on high glucose-inducing mesangial cells senescence. Mech Ageing Dev. 2012;133(6):387–400. · DOI
  151. Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, et al. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell. 2012;11(3):401–14. https://doi.org/10.1016/j.stem.2012.06.007. · DOI · Paper page
  152. Pospelova TV, Leontieva OV, Bykova TV, Zubova SG, Pospelov VA, Blagosklonny MV. Suppression of replicative senescence by rapamycin in rodent embryonic cells. Cell Cycle. 2012;11(12):2402–7. https://doi.org/10.4161/cc.20882. · DOI
  153. Lerner C, Bitto A, Pulliam D, Nacarelli T, Konigsberg M, Van Remmen H, et al. Reduced mammalian target of rapamycin activity facilitates mitochondrial retrograde signaling and increases life span in normal human fibroblasts. Aging Cell. 2013;12(6):966–77. https://doi.org/10.1111/acel.12122. · DOI
  154. Panganiban RA, Day RM. Inhibition of IGF-1R prevents ionizing radiation-induced primary endothelial cell senescence. PLoS One. 2013;8(10):e78589. https://doi.org/10.1371/journal.pone.0078589. · DOI
  155. Wang R, Yu Z, Sunchu B, Shoaf J, Dang I, Zhao S, et al. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism. Aging Cell. 2017;16(3):564–74. https://doi.org/10.1111/acel.12587. · DOI · Paper page
  156. Kawakami Y, Hambright WS, Takayama K, Mu X, Lu A, Cummins JH, et al. Rapamycin rescues age-related changes in muscle-derived stem/progenitor cells from progeroid mice. Mol Ther Methods Clin Dev. 2019;14:64–76. https://doi.org/10.1016/j.omtm.2019.05.011. · DOI

Cited by

Sorted by citations

Metadata

Authors
Selvarani, R., Mohammed, S., & Richardson, A.
Venue
GeroScience
Publisher
Springer Science and Business Media LLC
Published
2020-10-10
Volume
43
Issue
3
Pages
1135-1158
ISSN
  • 2509-2715
  • 2509-2723
DOI
10.1007/s11357-020-00274-1
PMC
PMC8190242
Cited by
290
References
26
Language
en
Licence
Funders
  • National Institute of health (R01AG045693, R01AG057424)
  • U.S. Department of Veterans Affairs (I01BX004538)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review